BCG VACCINE - AN INNOVATION FOR DIABETES TREATMENT IN PAKISTAN?

Authors

  • Zohair Lilani
  • Afrinah Ahmed
  • Rabbia Tazeem
  • Erum Naeem

Abstract

Pakistan is a third world country with very small health budget and a diabetes prevalence of about 6.9% among adults, accounting for over 86,000 deaths. If phase 2 trials testing the ability of BCG to reverse type 1 Diabetes become successful in remission of insulin from pancreas this would be very useful to treat diabetes in Pakistan as BCG is readily available, less expensive, has less storage problems, less side effects and doesn't require skilful person to administer. Keywords: Diabetes; BCG; Pakistan

References

International Diabetes Federation [Internet]. Diabetes in Pakistan - 2015.Available from: http://www.idf.org/membership/mena/pakistan. 2. Kathleen M. Gillespie. Type 1 diabetes: pathogenesis and prevention. CMAJ. 2006 Jul 18; 175(2): 165–70. 3. Denise L. Faustman,, Limei Wang, Yoshiaki Okubo, Douglas Burger, Liqin Ban, Guotong Man, Hui Zheng, David Schoenfeld, Richard Pompei,Joseph

J Ayub Med Coll Abbottabad 2017;29(1)

http://www.jamc.ayubmed.edu.pk 2

Avruch, and David M. Nathan et al. Proof-of-Concept, Randomized, Controlled Clinical Trial of BacillusCalmette-Guerin for Treatment of Long-Term Type 1 Diabetes. PLoS One. 2012; 7(8): e41756. 4. Shinichiro Ryu, Shohta Kodama, Kazuko Ryu, David A. Schoenfeld, and Denise L. Faustman. Reversal of established autoimmune diabetes by restoration of endogenous β cell function. J Clin Invest. 2001 Jul 1; 108(1): 63–72. 5. Marceline Huppmann, Andrea Baumgarten, DIPSOCSC, Anette-G. Ziegler, MD and Ezio Bonifacio,

PHD et al. Neonatal Bacille Calmette-Guerin Vaccination and Type 1 Diabetes. Diabetes Care 2005 May; 28(5): 1204-1206. 6. Allen HF1, Klingensmith GJ, Jensen P, Simoes E, Hayward A, Chase HP et al. Effect of Bacillus Calmette-Guerin vaccination on new-onset type 1 diabetes. A randomized clinical study. Diabetes Care. 1999 Oct;22(10):1703-7

Published

2017-03-01

Issue

Vol. 29 No. 1 (2017): JOURNAL OF AYUB MEDICAL COLLEGE, ABBOTTABAD

Section

EDITORIAL

License

Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License  CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.

USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.

AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.

Most read articles by the same author(s)